Madhav Dhodapkar, MD
Enriched profileScientific Director, Multiple Myeloma Program, Fred Hutch · Fred Hutchinson Cancer Center
Madhav Dhodapkar is Scientific Director, Multiple Myeloma Program, Fred Hutch at Fred Hutchinson Cancer Center. OpenAlex indexes 491 publications with 24,745 citations (h-index 71); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 21 Oct 2026
Overview
Updated 23 Oct 2026
Madhav Dhodapkar, MD, is Scientific Director, Multiple Myeloma Program, Fred Hutch at Fred Hutchinson Cancer Center. The public record shows 491 publications with 24,745 citations (h-index 71), centered on Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 7 companies, 5 NIH-funded awards (2025–2026).
- Most recent indexed publication: 2026 · Blood
- Top research focus: Multiple Myeloma Research and Treatments
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 37 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 181.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance
Sponsor: Fred Hutchinson Cancer Center
- Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Sponsor: Fred Hutchinson Cancer Center
- Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
Sponsor: Multiple Myeloma Research Consortium
Industry payments
Updated 23 Oct 2026
7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20258 payments$10,591openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year20244 payments
- Legend Biotech USA Inc.Program year20234 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
65.3%Thalidomide Analog65.3%Revlimid68%Lenalidomide32%Part D<11 patientsAnti-infectives
17.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor17.9%Valacyclovir100%Part D<11 patientsBlood & clotting
16.8%Factor Xa inhibitor16.8%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
5 NIH research awards on record, funded 2025–2026 per NIH RePORTER. The latest:
- Targeting microbial triggers of gammopathy for immunoprevention
Fred Hutchinson Cancer Center
FY2026$945,368UH3CA290302 - Engineering Effective T cell Immunity to Multiple Myeloma
Fred Hutchinson Cancer Center
FY2026$850,024P01CA018029 - Immune aging and outcomes in adult survivors of childhood cancer
Fred Hutchinson Cancer Center
FY2026$798,501R01AG098480
Congress activity
Updated 23 Oct 2026
94 congress contributions (2005–2025) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:
- Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Reading the "T" Leaves: Predicting Outcomes with Bispecific Antibodies in Multiple Myeloma.
Blood cancer discovery
Article2026 - Rethinking Multiple Myeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations.
Blood cancer discovery
Review2026
Most-cited works
by citation count (OpenAlex)- 01Antitumor Activity of Thalidomide in Refractory Multiple MyelomaArticle2,580 citations1999
- 02
- 03
- 04Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple MyelomaArticle908 citations2019
- 05
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/madhav-dhodapkar-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
targetedonc.com/authors/madhav-dhodapkar-mbbs
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →targetedonc.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- MB
BS, All India Institute of Medical Sciences (listed as MBBS)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Editorial & leadership roles
journal and society appointments- Elected member
American Society for Clinical Investigation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Secondary affiliations
appointments beyond the home institution- Professor
Division of Hematology and Oncology, University of Washington School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
David Maloney, MD, PhD
Fred Hutchinson Cancer Center
Brenda Sandmaier, MD
Fred Hutchinson Cancer Center
Lawrence Fong, MD
Fred Hutchinson Cancer Center
Anna Wald, MD, MPH
Fred Hutchinson Cancer Center
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens